All lobbying filings

MEHLMAN CONSULTING, INC.

Lobbying for ASSOCIATION OF ACCESSIBLE MEDICINES · Trade Association

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 7

S 1040
Drug Competition Enhancement Act
HR 5526
Biosimilar Red Tape Elimination Act
S 1954
Biosimilar Red Tape Elimination Act
HR 3269
ETHIC Act
S 43
Skinny Labels, Big Savings Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1302
Increasing Transparency in Generic Drug Applications Act

Lobbying activity 3

Medicare/Medicaid

Issues related to generic medicines.

Health Issues

Issues related to generic medicines. issues related to generic and biosimilar medications.

Pharmacy

Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.